These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29700899)

  • 1. Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta.
    Eto S; Hada S; Fukuhara R; Nishimura G; Takagi M
    Pediatr Int; 2018 May; 60(5):485-486. PubMed ID: 29700899
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S; Tavakkoli S
    J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease of serum alkaline phosphatase after three cycles of pamidronate disodium in children with severe osteogenesis imperfecta.
    Cabral de Menezes Filho H; Rodrigues JM; Radonsky V; Della Manna T; Kuperman H; Steinmetz L; Dichtchekenian V; Damiani D; Setian N
    Horm Res; 2007; 68 Suppl 5():207-8. PubMed ID: 18174750
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclic pamidronate treatment in Bruck syndrome: proposal of a new modality of treatment.
    Andiran N; Alikasifoglu A; Alanay Y; Yordam N
    Pediatr Int; 2008 Dec; 50(6):836-8. PubMed ID: 19067906
    [No Abstract]   [Full Text] [Related]  

  • 5. Experience with bisphosphonates in osteogenesis imperfecta.
    Glorieux FH
    Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Muscle weakness as presenting symptom of osteogenesis imperfecta.
    Boot AM; de Coo RF; Pals G; de Muinck Keizer-Schrama SM
    Eur J Pediatr; 2006 Jun; 165(6):392-4. PubMed ID: 16534588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
    Onwuneme C; Abdalla K; Cassidy N; Hensey O; Ryan S
    Arch Dis Child; 2007 Dec; 92(12):1087. PubMed ID: 18032639
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
    Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
    Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
    Yamashita S
    Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta.
    Amarasena S; Lekamwasam S; Jayawardena P
    Ceylon Med J; 2005 Sep; 50(3):137-8. PubMed ID: 16252586
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
    Land C; Rauch F; Montpetit K; Ruck-Gibis J; Glorieux FH
    J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two doses of pamidronate in infants with osteogenesis imperfecta.
    Senthilnathan S; Walker E; Bishop NJ
    Arch Dis Child; 2008 May; 93(5):398-400. PubMed ID: 18089634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS; Glorieux FH; Rauch F
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous pamidronate treatment in children with moderate-to-severe osteogenesis imperfecta started under three years of age.
    Alcausin MB; Briody J; Pacey V; Ault J; McQuade M; Bridge C; Engelbert RH; Sillence DO; Munns CF
    Horm Res Paediatr; 2013; 79(6):333-40. PubMed ID: 23735642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.